JAK inhibitors linked to shingles risk in IBD
Review reveals incidence of adverse events linked to the drug class
Patients with inflammatory bowel disease taking JAK inhibitors may be at increased risk for herpes zoster infection, according to the results of a meta-analysis.
Hepatogastroenterology researchers, from Nancy University Hospital in France and international colleagues, have investigated the safety profile of four JAK inhibitors — tofacitinib, upadacitinib, filgotinib and baricitinib — in patients with a range of immune-mediated diseases.
